Dating women in china with hpv
Shang-ying Hu, Bin Liu, Feng Chen, Jian-feng Cui, Xin-fu Liu, Unench Sharnuud, Wen-hua Zhang (CICAMS). Conflict of Interest: All authors have completed the Unified Competing Interest form at declare that their respective institutions received clinical trial funding from the Glaxo Smith Kline group of companies, through the Jiangsu Province CDC, the CICAMS (Beijing, China) and the National Institute for Food and Drug Control (NIFDC) (Beijing, China). Multiple hr HPV infections were reported for 24.4% of hr HPV DNA positive women.
Baseline HPV prevalence and type distribution data are reported from a phase II/III, double-blind, randomised, controlled study evaluating the efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine.
In China, cervical cancer is the second most frequent cancer among women aged 15–44 years.
The authors collected baseline data on prevalence and type distribution of human papillomavirus (HPV) from more than 6,000 healthy Chinese women aged 18–25 years participating in a large vaccine efficacy trial.
In order to promote vaccination and screening, it is essential to train heath care providers and educate the public about HPV and cervical cancer awareness.
This essay discusses the current burden of HPV-related cervical cancer and the barriers for women to accept HPV vaccine and cervical cancer screening, summarizes the challenges in China and suggests public health strategies to promote HPV vaccination and cervical cancer screening in China to reduce the incidence rate of cervical cancer as well as related health care costs.